We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The US Food and Drug Administration (FDA) has accepted Pfizer’s two new drug applications (NDAs) for tafamidis to treat transthyretin amyloid cardiomyopathy (ATTR-CM).....
Pfizer has anounced that the recent study has revealed, tafamidis drug reduced the risk of death for patients with a rare and fatal heart disease by around 30 per cent, boosting the prospects of what could be a billion-dollar-a-year drug.